# A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents

> **NCT01143077** · PHASE3 · COMPLETED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 244 (actual)

## Conditions studied

- Schizophrenia
- Schizoaffective Disorder

## Interventions

- **DRUG:** Lurasidone HCl

## Key facts

- **NCT ID:** NCT01143077
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-06
- **Primary completion:** 2011-05
- **Final completion:** 2011-05
- **Target enrollment:** 244 (ACTUAL)
- **Last updated:** 2013-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01143077

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01143077, "A Study Evaluating Lurasidone for The Treatment of Schizophrenia or Schizoaffective Disorder in Subjects Switched From Other Antipsychotic Agents". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT01143077. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*